Connect with us
Novo Nordisk completed the €10.66 billion acquisition of Catalent, including three production plants to scale up Wegovy production. Despite rivals' opposition, the deal secures Novo’s market...
Ozempic, manufactured by Novo Nordisk, gains EMA approval for chronic kidney disease, reducing disease progression by 24%, per the Flow trial. With 40% of type 2...
Novo Nordisk's experimental weight-loss pill, amycretin, showed promising early-phase results, with patients losing up to 13.1% of their weight in 12 weeks. Side effects were mild...
Denmark's GDP is expected to grow by 1.8% in 2024, revised down from 2.1%, with 2% growth anticipated in 2025. Denmark outpaces Nordic peers, with Sweden...
In the first half of the year, Novo Nordisk saw significant growth in sales, with Ozempic revenue up 36% to 56.685 billion crowns (€7.596 billion) and...
Eli Lilly is investing $5.3 billion in a new Indiana plant to increase production of diabetes and weight loss drugs, raising total facility investment to $9...
BaseLaunch, a Basel biotech incubator, gains support from AbbVie, joining Roche, Novo Nordisk, Johnson & Johnson, and CSL Behring. Operated by Basel Area Business & Innovation,...
Until now, in the field of anti-obesity treatments, there was a drug that attracted attention: Ozempic. It is also made by Novo Nordisk and is very...
Novo Nordisk sees substantial growth, reporting a 28% increase in profits to €3.4 billion in Q1 2024, with operating profits up 27% to €4.27 billion. This...
Wegovy stands as Novo Nordisk's big bet. This medicine was what placed the Danish multinational company as the most valuable company in Europe last September, surpassing...